EP Wealth Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.67M Sell
10,345
-5,710
-36% -$952K 0.01% 549
2026
Q2
$3.04M Buy
16,055
+1,495
+10% +$281K 0.01% 490
2026
Q1
$2.87M Sell
14,560
-49
-0.3% -$9.45K 0.01% 403
2025
Q4
$2.69M Sell
14,609
-829
-5% -$145K 0.01% 383
2025
Q2
$2.16M Sell
15,438
-84
-0.5% -$11.8K 0.01% 402
2025
Q1
$2.28M Buy
15,522
+1,373
+10% +$199K 0.02% 346
2024
Q4
$1.85M Buy
14,119
+3,901
+38% +$546K 0.02% 371
2024
Q3
$1.59M Buy
10,218
+1,692
+20% +$273K 0.01% 402
2024
Q2
$1.33M Buy
8,526
+366
+4% +$55.1K 0.01% 338
2024
Q1
$1.11M Sell
8,160
-581
-7% -$76.9K 0.01% 361
2023
Q4
$1.18M Buy
8,741
+919
+12% +$119K 0.02% 344
2023
Q3
$1.06M Buy
7,822
+357
+5% +$48.8K 0.02% 320
2023
Q2
$1.07M Buy
7,465
+18
+0.2% +$2.65K 0.02% 321
2023
Q1
$1.03M Sell
7,447
-1,199
-14% -$161K 0.02% 294
2022
Q4
$1.17M Buy
+8,646
New +$1.08M 0.02% 261
2022
Q3
– Sell
-5,858
Closed -$774K – 359
2022
Q2
$774K Buy
5,858
+1,741
+42% +$228K 0.02% 294
2022
Q1
$546K Sell
4,117
-127
-3% -$15.2K 0.01% 363
2021
Q4
$494K Sell
4,244
-256
-6% -$30.1K 0.01% 355
2021
Q3
$540K Buy
4,500
+989
+28% +$115K 0.01% 317
2021
Q2
$421K Buy
3,511
+386
+12% +$42.4K 0.01% 369
2021
Q1
$311K Buy
3,125
+9
+0.3% +$905 0.01% 401
2020
Q4
$312K Buy
+3,116
New +$330K 0.01% 338
2020
Q2
– Sell
-2,313
Closed -$207K – 369
2020
Q1
$207K Sell
2,313
-399
-15% -$37.6K 0.01% 345
2019
Q4
$270K Sell
2,712
-615
-18% -$57.9K 0.01% 348
2019
Q3
$297K Buy
+3,327
New +$288K 0.01% 282

Other funds holding AZN

EP Wealth Advisors's AZN Position: Q3 2026 in Review

EP Wealth Advisors reduced its AstraZeneca (AZN) stake by 36% in Q3 2026, selling an estimated $952K and leaving 10,345 shares worth $1.67M. The position accounts for 0.01% of the portfolio, ranked #549.

EP Wealth Advisors first reported a position in AZN in Q3 2019 and has held it in 25 quarters since. The position peaked at $3.04M in Q2 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • EP Wealth Advisors held 10,345 shares of AstraZeneca worth $1.67M as of Q3 2026.
  • EP Wealth Advisors sold 5,710 AstraZeneca shares in Q3 2026, an estimated $952K.
  • AstraZeneca made up 0.01% of EP Wealth Advisors's portfolio in Q3 2026, its #549 holding.
  • EP Wealth Advisors first reported a position in AstraZeneca in Q3 2019 and has held it in 25 quarters since.
  • EP Wealth Advisors's AstraZeneca position peaked at $3.04M in Q2 2026.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on EP Wealth Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.